Your Doctor Won't Tell You This About Bloodwork

Land provides personal evidence: his lead level was 101 µg/L in January and <1 µg/L in April, a 10x swing. He attributes the spike to a transient exposure from environment. He notes that inflammation markers rise with infections, heavy metals with ingestion, and hormones with sleep/stress. Conversely, kidney values and lipids are more stable. The principle is to avoid overreacting to a single data point while also not ignoring a persistent trend.

Land argues that many people test obsessively but continue unhealthy habits. He reminds that humans are creatures of habit; we prefer familiar foods and routines because they require less mental effort. However, if you commit to change based on results, you will adapt and eventually appreciate the health gains. He recommends using blood work to pinpoint specific areas for improvement rather than as an abstract data collection exercise.

Land warns against 'going crazy with blood work' while neglecting exercise, diet, and sleep. He points out that many people spend lots on tests but skip basic healthy behaviors. By fixing sleep, losing excess weight (e.g., 10 kg overweight), and exercising regularly, you can expect blood markers to improve automatically. The blood work then serves to reveal which specific areas still need attention, making the testing cost-effective and actionable.

Land uses CRP and triglycerides to show that normal thresholds (CRP <3, TG <150) still carry risk, while optimal values (CRP near 0, TG ~50) are associated with the lowest mortality. He references his book 'The Longevity Leap' which provides optimal ranges for 70+ markers based on 8,000 studies. He emphasizes that reference ranges get updated when evidence accumulates, so today's normal may already be suboptimal. This practice turns blood work into a precision tool rather than a disease-diagnosis-only instrument.

Land shares his personal experience: in January his blood lead was 101 µg/L, but retested in April it was under 1 µg/L — a tenfold drop. He attributes the spike to a transient exposure from food, water, or air. He notes that inflammation markers can rise and fall with infections, heavy metals with ingestion, and hormones with sleep and stress. Therefore, a pattern of abnormal results across two tests separated by weeks is needed before concern. Conversely, markers like glucose, kidney function, and lipids don't swing as wildly, so a single high glucose still warrants attention but should be confirmed. This framework prevents both overreaction and inaction.

Land illustrates with CRP: normal is <3 mg/L, but any level above 0.2 mg/L increases risk, and optimal for mortality is as close to zero as possible. Similarly, triglycerides were once accepted up to 250, then lowered to 150, and now evidence shows risk above 100, with optimal around 50 mg/dL. He argues that as new studies accumulate, reference ranges get updated, so they are not static dogma. He tells viewers to seek out the values seen in the top 1% of healthiest individuals, which he compiled in his book from 8,000 studies covering 70+ markers. This is a paradigm shift: instead of being satisfied with 'normal,' aim for the biomarker profile of the lowest risk cohort.

He walks through the diabetes spectrum: normal fasting glucose 70–90 mg/dL, pre-diabetic 100–125, diabetic >125; normal A1C 4.5–5.5%, pre-diabetic >5.6–6.4%, diabetic ≥6.5%. It takes years to progress from normal to pre-diabetes to full diabetes. By measuring blood sugar annually, you can spot an upward creep and intervene with diet and lifestyle. The same applies to kidney disease (declining eGFR from high blood sugar/pressure), metabolic syndrome (combination of high waist, high BP, high triglycerides, low HDL), and heart disease (elevated CRP, homocysteine, ApoB, LP(a) over decades). He states that understanding these trajectories is empowering because no one is destined to get these diseases; you can modify your risk.